(Reuters) -Johnson & Johnson on Tuesday suspended the sales forecast for its COVID-19 vaccine due to global supply surplus and demand uncertainty, sending its shares down 2.6% in premarket trading.

The previous forecasts for the shot were as high as $3.5B. However, the shots has performed poorly in comparison to other brands due to low sales in America and safety concerns.

Due to safety concerns, manufacturing bottlenecks and uneven demand for the vaccine, sales of this vaccine fell last year.